This led the authors to speculate that differences in the microbiome affect the glycerophospholipid metabolism, which alters IFN-γ and IL-2 expression in the tumor microenvironment, resulting in better anti-PD-1 response. The gene discussed is PDCD1; the disease is neoplasm.